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Abstract Rivaroxaban and other oral direct factor Xa
inhibitors (ODiXa) are currently developed for prophylaxis
and treatment of thromboembolic diseases using ﬁxed
doses. Although routine monitoring is not required,
assessing the intensity of anticoagulation may be useful
under certain clinical conditions. ODiXa prolong coagu-
lation times of several clotting assays and, thus, their
concentration may be determined in factor Xa speciﬁc
chromogenic substrate assays. So far, no standardized and
validated assay is commercially available. Here, ﬁve
methods (A through E) are studied and optimized to reduce
interassay variability. Human pooled plasma was spiked by
a serial dilution of rivaroxaban (25–900 ng/ml). The
release of para-nitroaniline from the chromogenic sub-
strates was measured by the optical density (OD) at
405 nm. Method B was identiﬁed to yield the lowest sum
of deviations from the mean value of the OD concentration
curve calculated from all assays. Spline functions were
developed for OD versus concentration curves for all
methods. The calculated OD versus concentration curves
overlapped for all methods. The coefﬁcient of variation for
all assays and concentrations of rivaroxaban decreased
from 25.3 ± 11.4% using the original data to 3.8 ± 2.2%
using the calculated data (P\0.0001). The robustness of
the chromogenic assay (method B) remains to be corrob-
orated in interlaboratory comparisons.
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Introduction
Oral direct factor Xa inhibitors (ODiXa) are currently
developed for prevention and treatment of thromboembolic
diseases with the aim to overcome the limitations of
the conventional anticoagulants unfractionated and low-
molecular-weight heparins (LMWHs), fondaparinux, and
vitamin-K antagonists [1]. One of the relevant advantages
of ODiXa is the alleged dispensability of laboratory mon-
itoring for dose adjustments [2, 3]. However, determination
of the anticoagulant effect may be desirable in certain
clinical situations such as acute bleeding, urgent surgery,
analysis of compliance, suspected overdose, substantial
decrease of renal or hepatic function, in elderly or children
populations [4].
Attempts to assess anticoagulation intensity by ODiXa
showed that inhibition of factor Xa activity, prolongation
of prothrombin time (PT) and activated partial thrombo-
plastin time (aPTT) correlate with plasma levels of the
ODiXa (rivaroxaban in this case) in healthy subjects and
those undergoing major orthopaedic surgery [5–8]. The
prolongation of PT values by rivaroxaban depends of the
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genic assays use heparin for standardization and data using
rivaroxaban are sparse. A preliminary standardization of
the reagents has been described using rivaroxaban [10].
Several factor Xa amidolytic chromogenic substrate assays
have been tested to speciﬁcally determine the concentration
of rivaroxaban; however, results of those methods show a
considerable interassay variability of up to 40% [11]. The
present paper aims at reducing the interassay variability
between various chromogenic substrate assays on human
plasma samples spiked with rivaroxaban.
Materials and methods
Rivaroxaban was isolated from commercially available
Xarelto
 (Bayer Healthcare Care, Wuppertal, Germany) by
extracting an aqueous suspension of the tablets with
dichloromethane at 25C. The compound was recrystal-
lized from dichloromethane and vacuum-dried. The purity
and identity were checked by 1H NMR spectroscopy, exact
molecular mass by high-resolution electrospray mass
spectrometry (Micromass Q-TOF ultima) and elemental
analysis. Pooled plasma was spiked with increasing con-
centrations of rivaroxaban (25–900 ng/ml) dissolved in
dimethyl sulfoxide (DMSO).
Blood was drawn from 20 healthy volunteers into
105 mmol/l sodium citrate (Sarstedt, Nuermbrecht, Ger-
many), centrifuged at 3,0009g for 15 min at 4 to obtain
platelet poor plasma (PPP). Pooled plasma was derived
from mixing PPP of 20 healthy persons. Plasma samples
were aliquoted, transferred into plastic tubes, shock frozen
and stored at -70 until analysed. Plasma samples were
thawed only once at 37, rivaroxaban was added at various
concentrations, and analysed in the assays within 2 h.
Donors gave informed consent prior to blood sampling.
Volunteers gave written informed consent.
Chromogenic anti-Xa assays
The test principle is based on the inhibitory action of riv-
aroxaban on coagulation factor Xa which speciﬁcally
cleaves para-nitroaniline (p-NA) linked to a chromogenic
peptide. Increasing rivaroxaban concentrations dose-
dependently inhibit the activity of factor Xa on the chro-
mogenic peptide and thereby the release of p-NA. The
concentration of rivaroxaban is plotted against the optical
density (OD) of released p-NA.
Reagents
The following factor Xa speciﬁc chromogenic substrates
were used: Coamatic Heparin assay (method A, S-2732
chromogenic substrate, Suc-isoleucine-glutamyl(gamma-
Pip)-glycine-arginine-pN-nitroaniline, Haemochrom Diag-
nostica GmbH, Essen, Germany), STA Rotachrom heparin
(method B, chromogenic substrate CBS 52.44, MAPA-
glycyl-argininyl-p-nitroaniline hydrochloride, Diagnostica
Stago, distributed by Roche-Diagnostika, Mannheim,
Germany), S2222 chromogenic substrate assay (method C,
N-benzoyl-L-isoleucyl-L-glutamylglycyl-L-arginine-p-nitro-
aniline hydrochloride and its methyl ester, Instrumentation
Laboratory GmbH, Kirchheim, Germany), STA-heparin
Liquid (method D, chromogenic substrate CBS-02.44,
MAPA-glycine-arginyl-p-nitroanilide, Asnie `res sur Seine,
France), and Technochrom anti-Xa (method E, chromo-
genic substrate succinyl-isoleucine-glutamyl-glycyl-argi-
nine-p-nitroaniline, Technoclone, Vienna, Austria).
Assay methodologies
All reagents were dissolved in the solvent provided by and
according to the description of the manufacturers. All
assays were run on microtiter plates and not on the
instruments proposed by the manufacturers. This was
decided to eliminate the variability of the experiments
caused by differences of the instructions by the manufac-
turers and coagulation analysers. Some manufacturers did
not have instructions for the determination of rivaroxaban
in the chromogenic assays. Preliminary experiments
revealed that the maximal OD at 405 nm in the absence of
rivaroxaban differed substantially between the assays using
the incubation procedures described below. Therefore, the
amounts of the chromogenic substrate and of factor Xa
were adjusted for every method to about 1.000 OD at
405 nm in the absence of rivaroxaban. The molar ratios of
the substrate and factor Xa were not changed for the
individual assays. 25 ll human plasma containing riva-
roxaban at various concentrations were diluted 1:5 with
25 ll normal pooled plasma followed, 25 ll factor Xa and
incubated at 37C for 5 min. 50 ll of synthetic chromo-
genic substrates were added and the samples incubated for
20 min. Samples were supplemented with 25 ll anti-
thrombin (stock solution 1 unit per ml) for the analysis with
the technochrom anti-Xa assay before addition of factor
Xa, as recommended by the manufacturer. The enzymatic
activity of factor Xa was stopped by adding 50 ll 50%
acetic acid. OD was recorded at 405 nm and converted to
rivaroxaban ng/ml plasma. Pooled plasma samples were
spiked with 25–900 ng/ml rivaroxaban. Blank plasma was
obtained by adding acetic acid prior to the chromogenic
substrate to each plasma sample. No dilutions of samples
containing high concentrations of rivaroxaban were per-
formed in these experiments. The OD value of the plasma
sample was subtracted from the OD of the test sample. The
assays were performed on microtiter plates in duplicates
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405 nm using the microtiter plate reader MR 7000 (soft-
ware version 3.2, Dynatech laboratories, Denkendorf,
Germany).
Statistical analysis
Summary statistics were computed for all OD values of all
concentrations of rivaroxaban and all methods. The chro-
mogenic assay with the lowest sum of the absolute dif-
ferences from the mean value of the OD concentration
curve calculated from all assays was deﬁned as the refer-
ence method (B). Spline functions were determined for
methods A, C, D, and E compared to method B. The t-test
for two paired samples was used to compare the differences
resulting from the data before and after introduction of the
standard method. The level of signiﬁcance was set at
P = 0.01. Statistical analyses were carried out using SAS/
STAT
 release 9.2 software (SAS Institute, Inc., Cary, NC,
USA).
Results
Recrystallized rivaroxaban is a colorless solid powder of
99% purity according to 1H NMR spectroscopy. High-
resolution electrospray mass spectrometry (Micromass
Q-TOF ultima) showed the identity of the compound. The
exact molecular mass was calculated for [M ? H] ? with
436.0740 (Ref. [12]: 436.0726), corresponding to
C19H18ClN3O5S with a molecular mass of 436.0734. Ele-
mental analysis determined the following C/H/N contents
(in %, calculated values in parenthesis): carbon 51.97
(52.36), hydrogen 4.23, nitrogen 9.54 (9.64). 1H NMR
chemical shifts (200 MHz, Bruker Avance) of extracted
rivaroxaban in d6-DMSO were in agreement with literature
data [12] (200 MHz, Bruker Avance).
Rivaroxaban was weighed using a calibrated analytical
balance. 3.0 mg Rivaroxaban were dissolved in 1 ml
dimethylsulfoxide (DMSO) and served as a stock solution.
DMSO did not inﬂuence the chromogenic factor Xa assays
up to 10 ll per ml plasma (data not shown).
Rivaroxaban dose-dependently inhibited factor Xa in all
chromogenic assays, i.e. in the presence of all chromogenic
substrates, over the range of 25–900 ng/ml plasma.
The original OD concentration curves are depicted in
Fig. 1. The coefﬁcients of variation (CV, mean values and
SD) of the methods using all ODs at all concentrations of
rivaroxaban were: method A 3.36 ? 2.19%, method B
2.02 ± 1.51%, method C 5.03 ± 4.79%, method D 2.81 ±
2.66%, and method E 5.43 ± 4.64%, respectively. The CV
value as well as the SD value was lowest for method B.
Calculating the difference of the individual methods
versus the mean value of all OD concentration curves,
method B turned out to expose the lowest sum of differ-
ences. Spline functions were calculated for methods A, C,
D, and E to minimize the difference against method B as
reference (Table 1). Correction of the original OD con-
centration curves by these functions resulted in almost
identical OD concentration curves for all methods (Fig. 2).
The differences of the CVs (mean and SD) of the methods
using the original data (Fig. 1, CV 25.3 ± 11.4%) and the
calculated data (Fig. 2, CV 3.8 ±2.2%) were signiﬁcant
(P\0.001).
The OD curves for method B versus the other methods
are shown in Fig. 3. Mathematical correction of the
methods A, C, D, and E eliminates the differences seen in
Fig. 3 (Fig. 4). The differences of the CVs (mean and SD)
of the data between Fig. 3 (CV 28.76 ± 13.53%) and
Fig. 4 (CV 4.16 ±2.47%) were signiﬁcant (P\0.001).
Fig. 1 OD concentration curves for ﬁve factor Xa speciﬁc chromo-
genic substrate methods as detailed in the method section
Table 1 Mathematical functions for methods A, C, D, and E to
reduce the differences compared to method B
Assay Method Equations
versus
method B
r
2
Coamatic A y = 0.2695x
3 - 1.2234x
2
? 2.1591x - 0.0379
0.9988
S2222 FXa C y = 3.239x
3 - 4.0879x
2
? 1.9418x - 0.0724
0.9919
STA liquid
anti Xa
Dy =- 0.0583x
3 - 0.1207x
2
? 1.2159x ? 0.0147
0.9994
Technochrom E y = 1.0851x
3 - 1.2646x
2
? 1.3108x - 0.0331
0.9986
This method was considered as provisional standard since it exposed
the lowest difference sum compared to the mean OD concentration
curve averaged from of all methods employed here
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Factor Xa speciﬁc chromogenic assays, originally designed
for indirect antithrombin dependent factor Xa inhibitors,
and are variably inﬂuenced by rivaroxaban. The results of
the present studies demonstrate that these differences can
be eliminated by mathematical modelling. In addition, one
assay (method B) was identiﬁed to possess the lowest
variation from the mean OD concentration curve calculated
from all ﬁve methods adopted in this study. A similar
approach was described for thromboplastin reagents to
determine the prothrombin time [9, 10]. One of seven
assays was identiﬁed to give the lowest variation when the
other prothrombin time assays were compared to this
alleged standard assay [11]. Another study used the
WHO-thromboplastin reagent to compute the calculations
for the commercially available thromboplastin reagents
using plasma samples spiked with rivaroxaban [13]. Both
approaches decreased the interassay variabilities. In the
present investigations this was also shown for the com-
parison of different chromogenic assays. A validation of
these results is currently ongoing in an interlaboratory
control study [14].
Although routine monitoring is not expected to be
needed for the new classes of small-molecule oral factor
Xa inhibitors, a clinical interest in identifying reliable and
readily available laboratory assays for measuring antico-
agulant effects of the new class of oral factor Xa inhibitors
is emerging. Clot-based methods such as prothrombin time
assays and factor Xa chromogenic substrate assays appear
to be the most reliable tools. Coagulation assays are
inexpensive and easy to perform, but in contrast to chro-
mogenic assays [15] they are affected by coagulation factor
abnormalities [16, 17] or levels of plasma proteins [15].
The concentration ranges of the chromogenic assays
used in this study should cover the range for low and high
doses of rivaroxaban used to prevent or the treat acute
thromboembolism. However, speciﬁc assay procedures
have been described also for low and high concentration of
rivaroxaban [10, 18]. This may be preferable in a clinical
routine laboratory. In our study, we adjusted the ratio of
factor Xa and of the chromogenic substrate of every assay
to obtain a similar maximal absorption by the release of the
chromophore in the absence of rivaroxaban. This has to be
performed for every assay by the manufacturer for routine
application as well as the potential value of anti-
thrombin added to the assay. The study presented here
identiﬁes an optimal chromogenic method to determine the
Fig. 2 Correction of the OD concentration curves of methods A, C,
D, and E by mathematical functions (see Table 1) to reduce the
difference to method B (provisional standard method)
Fig. 3 OD of method B versus the OD of methods A, C, D, and E
after normalization of the maximal OD for the same concentrations of
rivaroxaban used in Figs. 1 and 2
Fig. 4 Modiﬁcation of the OD of method B versus the OD of
methods A, C, D, and E by mathematical functions (see Table 1)t o
reduce the difference to method B for the same concentrations of
rivaroxaban used in Figs. 1 and 2
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123concentration of rivaroxaban and can be adopted for
additional chromogenic assays not included in our study.
Some limitations of the study have to be recognized.
First, the different assays were designed to be run in ways
which were as similar as possible; by this, it was not always
possible to comply with the instructions of the manufac-
turers. This includes the fact that incubation times were the
same for all methods, assays were run on the same
instrument and the chromogenic factor Xa concentration
modalities were modiﬁed to result in a similar OD in the
absence of rivaroxaban. Only by doing this, the assays
became comparable. Second, plasma samples were spiked
with rivaroxaban and no samples were used from patients
treated with rivaroxaban. These investigations are ongoing.
In summary, the present investigation demonstrates that
differences between factor Xa chromogenic assays exist
and that these differences can be reduced by mathematical
modelling. Chromogenic substrate assays were made
comparable for plasma samples spiked with rivaroxaban.
Further studies are undertaken to corroborate the mono-
centric experience. Method validation needs to be extended
to other chromogenic substrates, other coagulation ana-
lysers and samples from patients on rivaroxaban and its
impact on factor Xa speciﬁc chromogenic substrate assays.
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